Literature DB >> 25704283

Soluble ST2 as a prognostic marker in community-acquired pneumonia.

Masato Watanabe1, Hajime Takizawa2, Masaki Tamura2, Akira Nakajima2, Daisuke Kurai2, Haruyuki Ishii2, Saori Takata2, Keitaro Nakamoto2, Erei Sohara2, Koujirou Honda2, Masuo Nakamura2, Toshiya Inui2, Hiroo Wada2, Hajime Goto2.   

Abstract

OBJECTIVES: Community-acquired pneumonia (CAP) is associated with high mortality when initial treatment fails. Early identification of these patients allows physicians to modify treatments earlier, increasing survival.
METHODS: Ninety-one hospitalized patients with CAP were studied. Serum soluble ST2 levels were measured at diagnosis and at 3, 7, and 14 days (days 0, 3, 7, and 14) after the initiation of antimicrobial treatment. The predictive value of all-cause in-hospital mortality and the additive effect of soluble ST2 on the pneumonia severity index (PSI) were evaluated.
RESULTS: In univariate analysis, high serum levels of soluble ST2 at days 0, 3, 7, and 14 were predictive of death (hazard ratios: 3.1, 10.0, 12.0, and 22.6, respectively). In multivariate analysis, a combination of soluble ST2 at day 3 (above 2700 pg/ml) and PSI were predictive of death with higher accuracy than PSI alone (net reclassification improvement, 0.44; integrated discrimination improvement, 0.17; P = 0.001 for both). Specifically, simultaneous presence of high soluble ST2 (day 3) and a PSI of 5 was suggestive of higher mortality risk than a PSI of 5 alone (mortality 78% vs. 39%, respectively).
CONCLUSIONS: Soluble ST2 is prognostic indicator of CAP and can add to the predictive value of the PSI.
Copyright © 2015 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Biomarker; Infection; Severity; Suppression of tumorigenicity 2; Treatment

Mesh:

Substances:

Year:  2015        PMID: 25704283     DOI: 10.1016/j.jinf.2015.02.004

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  6 in total

1.  Diagnosis of chronic heart failure by the soluble suppression of tumorigenicity 2 and N-terminal pro-brain natriuretic peptide.

Authors:  Xiao-Ling Jin; Ning Huang; Hui Shang; Ming-Cheng Zhou; Yi Hong; Wen-Zheng Cai; Jie Huang
Journal:  J Clin Lab Anal       Date:  2017-07-18       Impact factor: 2.352

2.  Plasma Soluble Suppression of Tumorigenicity-2 Associates with Ventilator Liberation in Acute Hypoxemic Respiratory Failure.

Authors:  Jehan Alladina; Sean D Levy; Josalyn L Cho; Kelsey L Brait; Sowmya R Rao; Alexander Camacho; Kathryn A Hibbert; R Scott Harris; Benjamin D Medoff; James L Januzzi; B Taylor Thompson; Ednan K Bajwa
Journal:  Am J Respir Crit Care Med       Date:  2021-05-15       Impact factor: 21.405

3.  Serum sST2 levels predict severe exacerbation of asthma.

Authors:  Masato Watanabe; Keitaro Nakamoto; Toshiya Inui; Mitsuru Sada; Kojiro Honda; Masaki Tamura; Yukari Ogawa; Takuma Yokoyama; Takeshi Saraya; Daisuke Kurai; Haruyuki Ishii; Hajime Takizawa
Journal:  Respir Res       Date:  2018-09-03

4.  The Elevated Soluble ST2 Predicts No-Reflow Phenomenon in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

Authors:  Mustafa Umut Somuncu; Tunahan Akgun; Mustafa Ozan Cakır; Ferit Akgul; Nail Guven Serbest; Huseyin Karakurt; Murat Can; Ali Riza Demir
Journal:  J Atheroscler Thromb       Date:  2019-04-18       Impact factor: 4.928

5.  Soluble form of suppression of tumorigenicity-2 predicts clinical stability of inpatients with community-acquired pneumonia.

Authors:  Yifeng Zeng; Mingshan Xue; Teng Zhang; Shixue Sun; Runpei Lin; Ning Li; Peiyan Zheng; Yingjie Zhen; Haisheng Hu; Xiaohua Douglas Zhang; Baoqing Sun
Journal:  Exp Biol Med (Maywood)       Date:  2021-07-05

6.  IL-33/ST2 axis deficiency exacerbates neutrophil-dominant allergic airway inflammation.

Authors:  Qiyun Ma; Yan Qian; Jingxian Jiang; Jingjing Wu; Meijuan Song; Xinyu Li; Zhongqi Chen; Zhengxia Wang; Ranran Zhu; Zhixiao Sun; Mao Huang; Ningfei Ji; Mingshun Zhang
Journal:  Clin Transl Immunology       Date:  2021-06-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.